[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-177740-105":53,"doc-detail-177740-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","reimbursement-billing-considerations-for-clinical-trials-involving-cochlear-technology","Reimbursement & Billing Considerations for Clinical Trials Involving Cochlear Technology","","Guidance for principal investigators, clinical professionals, and institutions on reimbursement and billing considerations for clinical trials involving implantable hearing solutions technology. Coverage and billing require confirmation of Medicare and payer rules, including Investigational Device Exemptions (IDE), appropriate informed consent, investigational plans, and required monitoring and records. Emphasis is placed on medically necessary services that are actually performed and documented, with Category A and B IDE study notification and approval steps addressed for Medicare reimbursement decisions. Includes definitions of device categories and outlines routine cost principles and claim submission responsibilities.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":21,"@type":70,"position":76},"https://docshare.wps.com/template/invoices/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/reimbursement-billing-considerations-for-clinical-trials-involving-cochlear-technology/177740/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/reimbursement-billing-considerations-for-clinical-trials-involving-cochlear-technology/177740.png","ImageObject",442,249,{"name":88,"@type":89},"Mason","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-10-16","2026-09-02",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",8,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is an Investigational Device Exemption (IDE) and when is it required for clinical studies?","Question",{"text":109,"@type":110},"An IDE allows an investigational device to be used in a clinical study to collect safety and effectiveness data. Unless exempt, approved IDE is required before the study begins, including for clinical evaluations of certain modifications or new intended uses.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What must be in place for clinical evaluation of devices that are not FDA-approved or cleared for marketing?",{"text":114,"@type":110},"An investigational plan approved by an institutional review board (IRB) is required, with FDA IDE approval for significant risk devices. In addition, the study needs informed consent from patients, labeling indicating investigational use only, monitoring, and required records and reports.",{"name":116,"@type":107,"acceptedAnswer":117},"How do providers determine whether Medicare will cover Category A or B IDE studies before submitting claims?",{"text":118,"@type":110},"Providers must check the CMS Coverage Website to confirm whether CMS (or its designated entity) has approved the study for Medicare coverage prior to submitting claims. They are responsible for verifying approval status for Category A or B IDE studies.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},177740,1790530680,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":20,"category_name":21,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":76},5909887256941,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","FOR PRINCIPAL INVESTIGATORS, CLINICAL PROFESSIONALS & INSTITUTIONS\nReimbursement & Billing Considerations for Clinical Trials Involving CochlearTM Technology\nSpecial coverage and billing considerations should be reviewed for services that are provided in conjunction with clinical trials. The following outlines those considerations for government and commercial health plans.\nThis Information is provided as guidelines only to address the unique nature of implantable hearing solutions technology. This information does not constitute reimbursement or legal advice. Cochlear Americas makes no representation or warranty regarding this information or its completeness, accuracy, fitness for any purpose, timeliness, or that following these guidelines will result in any form of coverage or reimbursement from any insurance company or federal health care program payer. The information presented herein is subject to change at any time. This information cannot and does not contemplate all situations that a health care professional may encounter. To be sure that you have the most current and applicable information available for your unique circumstances, please consult your own experts and seek your own legal advice regarding your reimbursement and coding needs and the proper implementation of these guidelines. All products should be used according to their labeling. In all cases, services billed must be medically necessary, actually performed, and appropriately documented in the medical record.\nMedicare Information\nOverview:\nFor many studies involving devices, an investigator or sponsor must obtain an Investigational Device Exemption (IDE) from the FDA.  An investigational device exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data.  Investigational use also includes clinical evaluation of certain modifications or new intended uses of legally marketed devices. All clinical evaluations of investigational devices, unless exempt, must have an approved IDE before the study is initiated.\nClinical evaluation of devices that have not been approved or cleared by the FDA for marketing requires:\nan investigational plan approved by an institutional review board (IRB). If the study involves a significant risk device, the IDE must also be approved by FDA;\ninformed consent from all patients;\nlabeling stating that the device is for investigational use only;\nmonitoring of the study and;\nrequired records and reports.\nDefinitions:\nCategory A Device – an experimental device for which absolute risk of the device type has not been established (that is, initial questions regarding safety and effectiveness have not been resolved) and the FDA is unsure whether the device type can be safe and effective. (FDA, 2019)\nCategory B Device – a non-experimental/investigational device for which the incremental risk is the primary risk in question (that is, initial questions of safety and effectiveness of that device have been resolved) or it is known that the device type can be safe and effective because, for example, other manufacturers have obtained FDA pre-market approval or clearance for that device type. (FDA, 2019)\nRoutine Costs in Clinical Trials (Medicare)– as described in The National Coverage Determinations (NCD) for Routine Costs in Clinical Trials (310.1), routine costs are all items and services that are otherwise generally available to members (i.e., there exists a benefit category, it is not statutorily excluded, and there is not a national non-coverage decision) that are furnished during a clinical study and that would otherwise be furnished even if the member were not enrolled in a clinical trial and include:\nItems or services that are typically provided absent a clinical trial (e.g., conventional care);\nItems or services required solely for the provision of the investigational item or service (e.g., administration of a non-covered chemotherapeutic agent), the clinically appropriat","cbCaijJrcxd4USyL","https://ap.wps.com/l/cbCaijJrcxd4USyL","docx",95368,9,"English","# Medicare Information\n## Overview\n## Definitions\n## Routine Costs in Clinical Trials (Medicare)\n## Notification Requirements\n## Coverage\n### Category A IDE Studies","[{\"question\":\"What is an Investigational Device Exemption (IDE) and when is it required for clinical studies?\",\"answer\":\"An IDE allows an investigational device to be used in a clinical study to collect safety and effectiveness data. Unless exempt, approved IDE is required before the study begins, including for clinical evaluations of certain modifications or new intended uses.\"},{\"question\":\"What must be in place for clinical evaluation of devices that are not FDA-approved or cleared for marketing?\",\"answer\":\"An investigational plan approved by an institutional review board (IRB) is required, with FDA IDE approval for significant risk devices. In addition, the study needs informed consent from patients, labeling indicating investigational use only, monitoring, and required records and reports.\"},{\"question\":\"How do providers determine whether Medicare will cover Category A or B IDE studies before submitting claims?\",\"answer\":\"Providers must check the CMS Coverage Website to confirm whether CMS (or its designated entity) has approved the study for Medicare coverage prior to submitting claims. They are responsible for verifying approval status for Category A or B IDE studies.\"}]","Reimbursement & Billing Considerations for Clinical Trials Involving Cochlear Technology | DOCX",1788329031]